First-in-Human Study of Taletrectinib in Patients With Advanced Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
U.S. Phase I First-in-Human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients With Advanced Solid Tumors
Clin. Cancer Res 2020 Jun 26;[EPub Ahead of Print], KP Papadopoulos, E Borazanci, AT Shaw, R Katayama, Y Shimizu, VW Zhu, TY Sun, HA Wakelee, R Madison, AB Schrock, G Senaldi, N Nakao, H Hanzawa, M Tachibana, T Isoyama, K Nakamaru, C Deng, M Li, F Fan, Q Zhao, Y Gao, T Seto, PA Jänne, SI OuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.